Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:301-307

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimitropoulou, C.
Right arrow Articles by Carrier, G. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimitropoulou, C.
Right arrow Articles by Carrier, G. O.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Ion channels/membrane transport
Right arrow Signal transduction
Right arrow Other Vascular biology

(Hypertension. 2001;37:301.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Angiotensin II Relaxes Microvessels Via the AT2 Receptor and Ca2+-Activated K+ (BKCa) Channels

Christiana Dimitropoulou; Richard E. White; Leslie Fuchs; Hanfang Zhang; John D. Catravas; Gerald O. Carrier

From the Department of Pharmacology and Toxicology (C.D., R.E.W., L.F., J.D.C., G.O.C.) and the Vascular Biology Center (L.F., H.Z., J.D.C.), Medical College of Georgia, Augusta.

Correspondence to Dr Gerald O. Carrier, Department of Pharmacology and Toxicology, Medical College of Georgia, 1120 15th St, Augusta, GA 30912-2300. E-mail gcarrier{at}mail.mcg.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Angiotensin II (Ang II) is one of the most potent vasoconstrictor substances, yet paradoxically, Ang II may dilate certain vascular beds via an undefined mechanism. Ang II–induced vasoconstriction is mediated by the AT1 receptor, whereas the relative expression and functional importance of the AT2 receptor in regulating vascular resistance and blood pressure are unknown. We now report that Ang II induces relaxation of mesenteric microvessels and that this vasodilatory response was unaffected by losartan, an AT1 receptor antagonist, but was inhibited by PD123,319, a selective antagonist of AT2 receptors. In addition, reverse transcriptase–polymerase chain reaction studies revealed high amounts of AT2 receptor mRNA in smooth muscle from these same microvessels. Ang II–induced relaxation was inhibited by either tetraethylammonium or iberiotoxin, suggesting involvement of the large-conductance, calcium- and voltage-activated potassium (BKCa) channel. Subsequent whole-cell and single-channel patch-clamp studies on single myocytes demonstrated that Ang II increases the activity of BKCa channels. As in our tissue studies, the effect of Ang II on BKCa channels was inhibited by PD123,319, but not by losartan. In light of these consistent findings from tissue physiology, molecular studies, and cellular/molecular physiology, we conclude that Ang II relaxes microvessels via stimulation of the AT2 receptor with subsequent opening of BKCa channels, leading to membrane repolarization and vasodilation. These findings provide evidence for a novel endothelium-independent vasodilatory effect of Ang II.


Key Words: angiotensin II • receptors, angiotensin • potassium channels • patch-clamp techniques


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Many complications of hypertension and congestive heart failure are ameliorated by interdiction of the renin-angiotensin system, and agents that attenuate the effects of angiotensin II (Ang II) are now a first-line pharmacological antihypertensive intervention. Ang II induces constriction, hypertrophy, and proliferation of vascular smooth muscle via the AT1 receptor. It is generally assumed that the therapeutic effects of AT1 antagonists are due to direct receptor blockade; however, a secondary effect of these agents is increased plasma levels of Ang II,1 which may then activate AT2 receptors. This receptor bears only 34% sequence homology to the AT1 receptor2 3 and mediates growth inhibition4 and apoptosis5 of vascular smooth muscle. In contrast, very little is known about the role of AT2 receptors in regulating blood pressure. Both Ang II receptors are expressed in the vasculature, but AT2 receptor expression is heterogeneous with respect to vascular bed, species, and developmental stage.6 Nonetheless, evidence suggests that AT2 receptors modulate vascular contractility. AT2 receptors mediate endothelium-dependent vasodilation of renal arterioles.7 Furthermore, AT2-deficient mice exhibit an increased pressor response to Ang II,8 whereas overexpression of AT2 receptors enhances Ang II–induced endothelium-dependent vasodilation.9 These findings suggest that AT2 receptors mediate Ang II–induced vascular relaxation; however, the cellular/molecular basis of Ang II–induced vasodilation is not clearly defined, nor has an effector mechanism been identified.

The purpose of the present study was to investigate the expression and physiological role of AT2 receptors in the microvasculature. We now report significant expression of AT2 receptors in mesenteric microvessels from adult rats and also demonstrate that Ang II relaxes these vessels via AT2 receptor–mediated stimulation of the large-conductance, calcium- and voltage-activated potassium (BKCa) channel. These findings provide evidence for an endothelium-independent vasodilatory effect of Ang II on vascular smooth muscle cells and may help to explain the salutary effects of AT1 receptor antagonists on the cardiovascular system, (eg, reduced blood pressure and infarct size10 due to "indirect" stimulation of AT2 receptors).


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Isolated Microvessel Preparation
Fourth-order mesenteric arterial branches (200 to 300 µm in diameter) were isolated microscopically from male Sprague-Dawley rats (aged 14 to 16 weeks) in accordance with guidelines of the American Physiological Society for the humane treatment of experimental animals and prepared for measurement of intraluminal diameter by video dimension analysis as described previously.11 Vessels were allowed to equilibrate for 30 minutes and were preconstricted to {approx}45% of their resting diameter with endothelin-1 (ET-1). After the constriction reached a steady state level, a complete concentration-response relaxation to Ang II was performed. In additional vessels a concentration-response relationship for Ang II was measured in the presence of tetraethylammonium (TEA), iberiotoxin (IBTx), losartan, or PD123,319.

Reverse Transcriptase–Polymerase Chain Reaction
Smooth muscle cells from 5 mesenteric arteries for each RNA isolation (n=15 rats, 3 RNA isolations) were harvested and pooled for total RNA measurement. As a negative control, RNA was also extracted from rat liver. Total RNA was isolated with the use of Trizol Reagent (GIBCO BRL). Phase separation was achieved by addition of chloroform, and RNA was precipitated from the aqueous phase with isopropyl alcohol. The amount of RNA was determined spectrophotometrically at A260. Total RNA (1 to 1.5 µg) was treated with DNase I (GIBCO BRL) for 15 minutes at room temperature and reverse transcribed (RT) with oligo(dT) using SuperScript (GIBCO BRL). Aliquots of the RT products were amplified with Taq DNA polymerase (GIBCO BRL) with the use of gene-specific primers. Reverse transcriptase–polymerase chain reaction (RT-PCR) was performed as described previously with the use of primers derived from published cDNA sequences of the AT1B (accession X64052) and AT2 (accession D16840) receptors.12 Primer sequences for AT1B were 5'-GGC ATT ATC CGT GAC TGT GAA A-3' (forward) and 5'-CTG CTT AGC CCA AAT GGT CCT C-3' (reverse), and the final PCR product was 446 bp in length. Primer sequences for the AT2 were 5'-GGA GCG AGC ACA GAA TTG AAA GC-3' (forward) and 5'-TGC CCA GAG AGG AAG GGT TGC C-3' (reverse), and the final PCR product was 446 bp in length. PCR negative controls were (1) amplification of H2O and (2) non-RT samples that were obtained from the same RNA, processed in parallel with the RT reaction but without adding the RT enzyme. The PCR reaction mixtures were first denatured at 94°C for 4 minutes and then amplified for 35 or 38 cycles of 94°C for 40 seconds, 65°C for 1 minute, and 72°C for 1 minute. An aliquot of 10 µL of the RT-PCR amplified sample was fractionated by electrophoresis on 1.5% agarose gel and visualized with ethidium bromide stain.

Patch-Clamp Studies
Single myocytes were isolated by a modification of a procedure described previously,13 and potassium channel activity was recorded in either the whole-cell (amphotericin perforated patch) configuration or from cell-attached or inside-out patches as described previously.14 15 Briefly, for cell-attached patches several drops of cell suspension were placed in a recording chamber containing the following (mmol/L): 140 KCl, 10 MgCl2, 0.1 CaCl2, 10 HEPES, and 30 glucose (pH 7.4; 22°C to 25°C). Activity of single potassium channels was recorded in cell-attached patches by filling the patch pipette (2 to 5 M{Omega}) with Ringer’s solution, as follows (mmol/L): 110 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, and 10 HEPES. In experiments on inside-out patches, the bathing solution exposed to the cytoplasmic surface of the membrane consisted of the following (mmol/L): 60 K2SO4, 30 KCl, 2 MgCl2, 0.16 CaCl2, 1 BAPTA (10-7 M Ca++), 10 HEPES, 5 ATP, and 10 glucose (pH 7.4; 22°C to 25°C). The pipette solution was the same Ringer’s solution described above. Current voltage relations were obtained from whole-cell or single-channel amplitudes at potentials between -50 and +50 mV, and single-channel conductance was calculated from the slope of the current-voltage relationship fitted by linear regression. Average channel activity (NPo) in patches with multiple BKCa channels was determined as described previously.14

Drugs
TEA was obtained from Aldrich. Ang II, dithiothreitol, amphotericin B, glibenclamide, 4-aminopyridine, and ET-1 were purchased from Sigma Chemical. PD123,319 was obtained from Research Biochemical International, papain from Worthington Biochemical Corp, and losartan from DuPont-NEN.

Statistical Analysis
All data were expressed as mean±SE except data from tension studies, which were expressed as percentage of maximum relaxation. Statistical significance between 2 groups was evaluated with Student’s t test, and a 1-way ANOVA was performed to evaluate significance between multiple groups. A P value <0.05 was considered to reflect a significant difference.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Ang II Dilates Microvessels Via the AT2 Receptor
Baseline intraluminal diameter of microvessels (intraluminal pressure=40 mm Hg) was 226±12 µm (n >30). Vessels were preconstricted to {approx}45% of the original baseline diameter with ET-1 (diameter reduced from 229±14 to 126±8 µm). In the absence of Ang II, ET-1–induced contraction was maintained for >60 minutes. A complete concentration-response curve for Ang II was then obtained. A typical tracing of Ang II–induced microvascular relaxation is illustrated in Figure 1A. On average, Ang II (0.1 to 300 nmol/L) induced a concentration-dependent relaxation with a maximum of 72±5% (Figure 1B; n=19). Pretreating microvessels with N-nitro-L-arginine (0.1 mmol/L; 30 minutes) had no effect on Ang II–induced relaxation (78±6%; n=4). A similar response to Ang II (78±3%; n=5) was obtained in microvessels pretreated for 30 minutes with 10 µmol/L losartan, a selective AT1 receptor antagonist (Figure 1B). In contrast, Ang II induced only 31±8% relaxation (n=10; Figure 1B) in microvessels pretreated for 30 minutes with 100 nmol/L PD123,319, a selective AT2 receptor antagonist. Pretreatment with these blocking agents did not affect baseline intraluminal diameter (Table). These studies indicate involvement of the AT2 receptor in Ang II–induced vasodilation, and subsequent molecular studies were designed to verify expression of this protein in rat mesenteric microvessels.



View larger version (36K):
[in this window]
[in a new window]
 
Figure 1. Ang II relaxes mesenteric microvessels via activation of AT2 receptors. A, Representative tracing of a concentration-response relationship to Ang II in a mesenteric small artery precontracted with ET-1. Ang II produced a concentration-dependent relaxation of 79%. Addition of acetylcholine (Ach) (30 µmol/L) further relaxed the vessel 100%. Intraluminal diameter (ID) in micrometers and a time scale in seconds are shown. B, Average concentration-response relationships for Ang II–induced vasodilation of microvessels under control conditions (n=13) or after a 30-minute pretreatment with either 10 µmol/L losartan (n=5) or 100 nmol/L PD123,319 (n=10). Each point represents the mean±SE relaxation response of n determinations. C, Analysis of Ang II type 1B or type 2 receptor mRNA by RT-PCR in rat mesenteric artery smooth muscle cells (SMC) and liver, as indicated by the lines above the gel. RT-PCR products (10 µL) were separated on 1.5% agarose gel by electrophoresis and stained with ethidium bromide. Arrows denote the DNA size marker. The sizes for the AT1B and AT2 receptors and ß-actin are 346, 446, and 276 bp, respectively. The gel is representative of 3 separate RNA samples from mesenteric arterial SMC.


View this table:
[in this window]
[in a new window]
 
Table 1. Intraluminal Diameters of Mesenteric Microvessels

Ang II Receptor mRNA
Representative gels of AT1B and AT2 receptor mRNA from isolated mesenteric microvascular smooth muscle cells analyzed by RT-PCR are provided in Figure 1C. Each isolation was examined microscopically to ensure against contamination with other cell types; nonetheless, it is possible that some minor degree of contamination may have been present. Analysis consistently detected AT2 receptor mRNA. In contrast, amplification of liver RNA did not reveal any bands for Ang II receptor mRNA. Absence or very low copy of these Ang II receptors in liver is consistent with previous studies,16 17 whereas mRNA for ß-actin was well detected in liver by RT-PCR.

Ang II–Induced Vasodilation Involves K+ Channels
We have demonstrated previously that disrupting the gradient for potassium efflux with high extracellular [K+] inhibits potassium channel–mediated vasorelaxation.11 14 18 To investigate whether AT2 receptor–mediated vasodilation is dependent on K+ efflux, microvessels were preconstricted with 80 mmol/L K+. Ang II did not affect KCl-contracted arteries (data not shown). In microvessels preconstricted with ET-1, Ang II–induced relaxation was measured after a 30-minute pretreatment with a potassium channel inhibitor: 1 mmol/L TEA (n=4; Figure 2A) or 100 nmol/L IBTx (n=4; Figure 2B). In the presence of these agents, even high concentrations of Ang II failed to produce significant relaxation. In contrast, subsequent treatment of microvessels with 10 µmol/L acetylcholine relaxed the microvessels 70±14% (TEA; n=4) or 73±10% (IBTx; n=4).



View larger version (18K):
[in this window]
[in a new window]
 
Figure 2. Ang II–induced relaxation of microvessels is mediated by potassium channels. A, Average concentration-response relationship for Ang II relaxation of mesenteric microvessels in the presence of 1 mmol/L TEA. After addition of 1 µmol/L Ang II had no effect, subsequent addition of 10 µmol/L acetylcholine induced significant relaxation of the vessels. Each point represents the mean±SE of 4 experiments. B, Average concentration-response relationship for Ang II relaxation of mesenteric microvessels in the presence of 100 nmol/L IBTx. After addition of 1 µmol/L Ang II had no effect, subsequent addition of 10 µmol/L acetylcholine induced significant relaxation of the vessels. Each point represents the mean±SE of 4 experiments. C, Superimposed whole-cell current tracings from single mesenteric myocytes recorded with the perforated patch configuration. Cells were voltage-clamped at a holding potential of -50 mV, and currents were elicited by 100 ms depolarizing pulses to -40, -10, 20, or 50 mV before or 10 to 15 minutes after exposure to 100 nmol/L Ang II. In the right panel, the effect of subsequent addition of 1 mmol/L TEA is illustrated. Dashed line indicates baseline current. D, Complete current-voltage relationship for steady state outward current (holding potential=-50 mV) before and 10 to 15 minutes after addition of 100 nmol/L Ang II. The effect of subsequent addition of 1 mmol/L TEA on the same cell is also plotted.

Ang II Increases Potassium Currents in Single Myocytes
Direct evidence that Ang II stimulated outward potassium currents in microvascular myocytes was obtained from whole-cell (perforated patch) patch-clamp recordings. Ang II (100 nmol/L) increased macroscopic outward current over the entire range of membrane voltages. For example, at +50 mV Ang II nearly tripled (287±35%; n=7; P<0.001) the steady state outward current. Representative tracings illustrating the effect of Ang II are provided in Figure 2C. The stimulatory effect of Ang II was reversed completely by subsequent treatment with 1 mmol/L TEA. A lower concentration of Ang II (10 nmol/L) nearly doubled (93±12% at +50 mV; n=3; P<0.05) steady state outward currents, and the effect was again abolished by 1 mmol/L TEA (decreased 27±3% below control values). The complete current-voltage relationship for these experiments is illustrated in Figure 2D. In contrast to TEA, neither 4-aminopyridine (1 mmol/L; n=3), a blocker of the delayed rectifier K+ channel, nor glibenclamide (10 µmol/L; n=3), a blocker of the ATP-sensitive K+ channel, affected Ang II–stimulated outward current (data not shown). These findings strongly suggested that the BKCa channel mediated Ang II–induced relaxation of microvessels, and subsequent single-channel studies were undertaken to prove this hypothesis.

Ang II Stimulates BKCa Channel Activity
Ang II stimulated the activity of single potassium channels in mesenteric myocytes. As illustrated in Figure 3A, there was minimal channel activity in cell-attached patches under control conditions (NPo <0.001 at +50 mV). However, channel activity was increased dramatically by 100 nmol/L Ang II (NPo 0.92; 15 minutes; Figure 3A), and this effect was concentration dependent (Figure 3B). Identification of this protein as the BKCa channel was demonstrated from experiments on cell-free inside-out patches in symmetrical concentrations of potassium (140 mmol/L). A complete current-voltage relationship for channel activity (Figure 3C) yielded a high single-channel conductance of 158±5 picoSiemens (n=3 to 5 inside-out patches). In addition, raising the concentration of calcium at the cytoplasmic surface of the membrane from 100 nmol/L to 100 µmol/L produced a substantial increase in channel gating behavior (Figure 4, top panel). These experiments identify this protein as the high-conductance, Ca2+-activated (BKCa) channel. In contrast to its effects on BKCa channels in cell-attached patches, addition of 100 nmol/L Ang II to the cytoplasmic surface of an inside-out patch had no effect on channel activity (n=3).



View larger version (33K):
[in this window]
[in a new window]
 
Figure 3. Ang II stimulates the activity of single BKCa channels in myocytes from mesenteric microvessels. A, Current tracings from the same cell-attached patch (+50 mV) before and 10 minutes after addition of 100 nmol/L Ang II. Channel openings are upward deflections from baseline (closed) state, as indicated by dashed line. B, Average activity (NPo) of BKCa channels recorded from cell-attached patches before and 10 to 15 minutes after addition of either 6 (n =4), 60 (n=4), or 100 nmol/L (n=6) Ang II. *Significant increase in channel NPo compared with control level. C, Average current-voltage relationship for single-channel activity recorded from inside-out patches with symmetrical (140 mmol/L) K+. Each point represents the mean±SE current of 3 to 5 patches, with the line fit by linear regression.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 4. AT2 receptors mediate the stimulatory effect of Ang II on BKCa channels. Channel openings (+50 mV) are upward deflections from baseline (closed) state, as indicated by the dashed line. Top tracing, Recordings from the same inside-out patch with either 100 nmol/L or 100 µmol/L [Ca2+] in the solution at the cytoplasmic surface of the membrane, as indicated by the arrows. Ang II (100 nmol/L; 15-minute pretreatment) was also present in the bath solution. Second tracing, Recordings from the same cell-attached patch before and 10 minutes after addition of 100 nmol/L Ang II to the batch solution, as indicated by arrow. Third tracing, Recordings from the same cell-attached patch. Cell was pretreated with losartan (10 µmol/L; 30 minutes), and recordings were then taken before and 15 minutes after subsequent addition of 100 nmol/L Ang II, as indicated by arrow. Bottom tracing, Recordings from the same cell-attached patch. Cell was pretreated with PD123,319 (100 nmol/L; 30 minutes). Recordings were then taken before and 15 minutes after subsequent addition of 100 nmol/L Ang II, as indicated by arrow.

AT2 Receptors Mediate Ang II Stimulation of BKCa Channels
Ang II receptor antagonists were used to determine which receptor mediated the stimulatory effect of Ang II on BKCa channels. Channel activity stimulated by 100 nmol/L Ang II is illustrated in Figure 4 under control conditions (panel 2) or after a 30-minute pretreatment with 10 µmol/L losartan (panel 3). Blockade of AT1 receptors with losartan did not affect Ang II–induced channel activity. On average, control NPo was 0.001±0.02, and after exposure to 100 nmol/L Ang II NPo increased to 0.86±0.02 (n=4). Blockade of AT2 receptors, on the other hand, completely prevented the stimulatory effect of Ang II. In the presence of PD123,319 (100 nmol/L, 30 minutes), 100 nmol/L Ang II had no effect on BKCa channel activity (NPo PD123,319, <0.001; PD123,310+Ang II, <0.001; n=4; bottom panel).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
We have demonstrated that Ang II relaxes mesenteric microvessels via a mechanism involving the AT2 receptor and BKCa channel activity, and this mechanism of Ang II action on intact tissues was confirmed by molecular studies on isolated microvascular myocytes demonstrating (1) expression of AT2 receptor mRNA and (2) AT2 receptor–mediated stimulation of BKCa channel activity in cell-attached patches. These findings provide evidence for a novel endothelium-independent effect of Ang II on the microvasculature. Previous studies suggest that Ang II relaxes cerebral microvessels19 20 or renal afferent arterioles7 by an endothelium-dependent mechanism, probably involving release of bradykinin and endothelium-derived dilators (eg, NO).9 10 In the present study, however, pretreating mesenteric microvessels with N-nitro-L-arginine did not affect Ang II–induced relaxation, suggesting that endothelium-derived NO does not play a role in the response of this vascular bed to Ang II. More directly, in the absence of endothelium Ang II clearly stimulated activity of BKCa channels in isolated myocytes.

Previous studies indicated that Ang II stimulates both whole-cell21 and single-channel22 potassium currents in cultured neurons via the AT2 receptor; however, this is the first study on the effects of Ang II on K+ channels in smooth muscle cells. Our studies demonstrate that Ang II increases both whole-cell and single-channel BKCa currents in mesenteric myocytes. Instead of traditional whole-cell recordings that require dialysis of the cytoplasm with exogenous calcium buffers, we used the perforated patch configuration to obtain whole-cell currents from "metabolically intact" myocytes. These findings indicated that Ang II increases a TEA-sensitive outward current in these cells, and subsequent single-channel studies revealed that this channel had a high conductance (>150 picoSiemens) and was stimulated by increasing "intracellular" calcium levels in inside-out patches. Therefore, we have identified this protein as the BKCa channel that is highly expressed in vascular smooth muscle and other cell types. Like other vascular smooth muscle cells, myocytes from mesenteric microvessels possess substantial outward K+ currents composed primarily of K+ efflux through BKCa channels.11 Because of their large conductance and high density of expression, these channels help to set and maintain the resting membrane potential of vascular smooth muscle.23 When intracellular [Ca2+] levels increase during contraction, BKCa channels provide an important repolarizing negative feedback mechanism that helps to reverse active contraction. Given the importance of BKCa channels in regulating vascular tone, these proteins constitute a powerful effector mechanism that mediates microvascular relaxation induced by a variety of vasodilatory agents, eg, nitrovasodilators.11 Our studies indicated that microvascular relaxation required physiological gradients of [K+] suitable for potassium efflux, suggesting involvement of potassium channels. Although several species of K+ channels are also expressed in vascular smooth muscle, we did not observe significant effects of Ang II on other channel species at the single-channel level. Moreover, neither glibenclamide (KATP channel antagonist) nor 4-aminopyridine (delayed rectifier channel antagonist) affected Ang II–stimulated whole-cell currents. In contrast, selective blockade of BKCa channels (with either 1 mmol/L TEA or 100 nmol/L IBTx; Figure 2) abolished Ang II–induced relaxation. Although TEA can block several species of potassium channels, at this low concentration it exhibits selectivity for the BKCa channel. IBTx, on the other hand, is a highly selective BKCa channel antagonist. Moreover, our single-channel patch-clamp data clearly identified the BKCa channel as a primary target of Ang II action in microvascular myocytes, and our findings that PD123,319 (but not losartan) inhibited this stimulatory effect of Ang II further implicate the BKCa channel as an effector molecule for AT2 receptor–mediated vasodilation. Although our findings clearly demonstrate an endothelium-independent effect of Ang II on microvascular myocytes, the vasodilatory response to Ang II in vivo would probably involve both endothelium-dependent and -independent mechanisms. In either case, our data obtained from intact tissues or single myocytes indicate that BKCa channels expressed in microvascular smooth muscle cells are the critical effector molecules involved in AT2 receptor–mediated relaxation of microvessels.

The signaling process linking AT2 receptors to BKCa channels in vascular smooth muscle is poorly understood. For example, metabolites of arachidonic acid might play a role in the response of BKCa channels to Ang II in mesangial cells; however, it is unclear whether the response of BKCa channels in these cells is mediated via AT1 and/or AT2 receptors.24 Therefore, it is difficult to draw strict comparisons between these 2 studies on different cell types and species. Nonetheless, because arachidonic acid metabolites open BKCa channels in other arteries,25 a potential role of arachidonic acid in mediating the response of mesenteric microvessels to Ang II remains a possibility. Alternatively, BKCa channels could be opened indirectly by Ang II–stimulated intracellular calcium. Although we have not tested this hypothesis conclusively, we do not believe that direct activation by calcium plays a major role because of the following: (1) Ang II induces vasodilation; therefore, the putative increase in calcium would have to be minimal and probably localized to the more peripheral regions of the cytoplasm near the BKCa channels. Such a "calcium-spark" model is possible, but we are unaware of any studies suggesting that Ang II stimulates such a mechanism in microvessels. (2) Ang II produced no obvious shift in the voltage sensitivity of outward currents, whereas increased [Ca2+]i shifts the sensitivity of BKCa channels to more negative potentials. In contrast, the effect of Ang II appears to be due mainly to increased current amplitude rather than increased voltage sensitivity. In contrast to the aforementioned mechanisms, it is clear that cyclic nucleotide–dependent vasodilators open BKCa channels in vascular smooth muscle.15 In the present study, however, inhibitors of either the cAMP- or the cGMP-dependent protein kinase had no effect on Ang II–stimulated BKCa channel activity (data not shown). These data suggest that a more novel mechanism of action underlies the effect of Ang II in microvessels; however, further experiments are necessary to elucidate the transduction mechanism coupling AT2 receptors to BKCa channels.

It is clear that AT2-induced vasodilation affects blood pressure. Animals lacking AT2 receptors exhibit an enhanced pressor response to Ang II,26 whereas overexpression of AT2 receptors antagonizes AT1 receptor–mediated pressor effects.9 AT2 receptor–mediated vasodilation, particularly of microvessels, may serve as a negative feedback mechanism to counterbalance the potent vasoconstrictor effect of AT1 receptor activation. For example, Ang II levels are increased during exercise,27 and AT2 receptor–mediated dilation of precapillary vessels might help to offset potentially dangerous effects of diminished capillary perfusion in face of excessive AT1 receptor stimulation. Therapeutically, it seems clear that AT2 receptors mediate salutary responses. For example, AT2 receptor stimulation may play a part in the antihypertensive effects of AT1 receptor antagonists, which increase plasma Ang II levels. In addition, our proposed "endothelium-independent" vasodilatory effect of Ang II could constitute a protective vasodilatory mechanism to preserve tissue perfusion when the endothelium is damaged as a result of atherosclerosis and/or hemodynamic stress. Interestingly, activation of AT2 receptors reduces infarct size.10 The present findings are the first to provide direct experimental evidence for a novel molecular effector (the BKCa channel) that can mediate endothelium-independent relaxation of vascular smooth muscle via Ang II stimulation of the AT2 receptor. Future studies will identify and characterize the postreceptor signal transduction cascade stimulated by Ang II in these microvessels.


*    Acknowledgments
 
This work was supported by grants from the American Heart Association (R.E.W., G.O.C., L.F.) and the National Institutes of Health (HL-54844, R.E.W.; HL-64779, R.E.W., G.O.C.; HL-52958, J.D.C.).

Received May 15, 2000; first decision June 6, 2000; accepted August 29, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Hubner R, Hogemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997;11(suppl 2):S19–S25.

2. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 1993;268:24539–24542.[Abstract/Free Full Text]

3. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993;268:24543–24546.[Abstract/Free Full Text]

4. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663–10667.[Abstract/Free Full Text]

5. Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci. 1998;63:L289–L295.

6. de Gasparo M, Siragy HM. The AT2 receptor: fact, fancy and fantasy. Regul Pept. 1999;81:11–24.[Medline] [Order article via Infotrieve]

7. Arima S, Endo Y, Yaoita H, Omata K, Ogawa S, Tsunoda K, Abe M, Takeuchi K, Abe K, Ito S. Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest. 1997;100:2816–2823.[Medline] [Order article via Infotrieve]

8. Akishita M, Yamada H, Dzau VJ, Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochem Biophys Res Commun. 1999;261:345–349.[Medline] [Order article via Infotrieve]

9. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925–935.[Medline] [Order article via Infotrieve]

10. Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs [published correction appears in J Am Coll Cardiol. 1999;33:591]. J Am Coll Cardiol. 1998;32:1787–1796.[Free Full Text]

11. Carrier GO, Fuchs LC, Winecoff AP, Giulumian AD, White RE. Nitrovasodilators relax mesenteric microvessels by cGMP-induced stimulation of Ca-activated K channels. Am J Physiol. 1997;273:H76–H84.[Abstract/Free Full Text]

12. Miyata N, Park F, Li XF, Cowley AW Jr. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol. 1999;277:F437–F446.

13. Clapp LH, Gurney AM. Outward currents in rabbit pulmonary artery cells dissociated with a new technique. Exp Physiol. 1991;76:677–693.[Abstract]

14. White RE, Darkow DJ, Lang JL. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res. 1995;77:936–942.[Abstract/Free Full Text]

15. White RE, Kryman JP, El-Mowafy AM, Han G, Carrier GO. cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BKCa channel activity in coronary artery smooth muscle cells. Circ Res. 2000;86:897–905.[Abstract/Free Full Text]

16. Nora EH, Munzenmaier DH, Hansen-Smith FM, Lombard JH, Greene AS. Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle. Am J Physiol. 1998;275:H1395–H1403.

17. Shanmugam S, Sandberg K. Ontogeny of angiotensin II receptors. Cell Biol Int. 1996;20:169–176.[Medline] [Order article via Infotrieve]

18. Han G KJ, McMillin PJP, White RE, Carrier GO. A novel transduction mechanism mediating dopamine-induced vascular relaxation: opening of BKCa channels by cyclic AMP-induced stimulation of the cyclic GMP-dependent protein kinase. J Cardiovasc Pharmacol. 1999;34:619–627.[Medline] [Order article via Infotrieve]

19. Haberl RL, Anneser F, Villringer A, Einhaupl KM. Angiotensin II induces endothelium-dependent vasodilation of rat cerebral arterioles. Am J Physiol. 1990;258:H1840–H1846.[Abstract/Free Full Text]

20. Haberl RL, Decker PJ, Einhaupl KM. Angiotensin degradation products mediate endothelium-dependent dilation of rabbit brain arterioles. Circ Res. 1991;68:1621–1627.[Abstract/Free Full Text]

21. Kang J, Sumners C, Posner P. Angiotensin II type 2 receptor-modulated changes in potassium currents in cultured neurons. Am J Physiol. 1993;265:C607–C616.[Abstract/Free Full Text]

22. Martens JR, Wang D, Sumners C, Posner P, Gelband CH. Angiotensin II type 2 receptor-mediated regulation of rat neuronal K+ channels. Circ Res. 1996;79:302–309.[Abstract/Free Full Text]

23. Trieschmann U, Isenberg G. Ca2+-activated K+ channels contribute to the resting potential of vascular myocytes: Ca2+-sensitivity is increased by intracellular Mg2+-ions. Pflugers Arch. 1989;414:S183–S184.

24. Stockand JD, Silverman M, Hall D, Derr T, Kubacak B, Sansom SC. Arachidonic acid potentiates the feedback response of mesangial BKCa channels to angiotensin II. Am J Physiol. 1998;274:F658–F664.

25. Barlow RS, El-Mowafy AM, White RE. H2O2 opens BKCa channels via the PLA2-arachidonic acid signaling cascade in coronary artery smooth muscle. Am J Physiol. 2000;279:H475–H483.

26. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377:748–750.[Medline] [Order article via Infotrieve]

27. Stebbins CL, Symons JD. Role of angiotensin II in hemodynamic responses to dynamic exercise in miniswine. J Appl Physiol. 1995;78:185–190. [Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. K. Stennett, X. Qiao, A. E. Falone, V. V. Koledova, and R. A. Khalil
Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats
Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H745 - H755.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. H. Lee, S. Xia, and L. Ragolia
Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R144 - R154.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Guilluy, M. Rolli-Derkinderen, L. Loufrani, A. Bourge, D. Henrion, L. Sabourin, G. Loirand, and P. Pacaud
Ste20-Related Kinase SLK Phosphorylates Ser188 of RhoA to Induce Vasodilation in Response to Angiotensin II Type 2 Receptor Activation
Circ. Res., May 23, 2008; 102(10): 1265 - 1274.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W. S. Park, J.-H. Ko, N. Kim, Y. K. Son, S. H. Kang, M. Warda, I. D. Jung, Y.-M. Park, and J. Han
Increased Inhibition of Inward Rectifier K+ Channels by Angiotensin II in Small-Diameter Coronary Artery of Isoproterenol-Induced Hypertrophied Model
Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1768 - 1775.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J.-M. Vincent, Y. W. Kwan, S. Lung Chan, C. Perrin-Sarrado, J. Atkinson, and J.-M. Chillon
Constrictor and Dilator Effects of Angiotensin II on Cerebral Arterioles
Stroke, December 1, 2005; 36(12): 2691 - 2695.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
K. M. Gauthier, D. X. Zhang, E. M. Edwards, B. Holmes, and W. B. Campbell
Angiotensin II Dilates Bovine Adrenal Cortical Arterioles: Role of Endothelial Nitric Oxide
Endocrinology, August 1, 2005; 146(8): 3319 - 3324.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Guimaraes and H. Pinheiro
Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunctionally
Cardiovasc Res, August 1, 2005; 67(2): 208 - 215.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. M. Duke, R. G. Evans, and R. E Widdop
AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats
Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2289 - H2297.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. L. Pallone
Microvascular Effects of Aldosterone and Angiotensin Type 2 Receptors
Hypertension, May 1, 2005; 45(5): 845 - 846.
[Full Text] [PDF]


Home page
HypertensionHome page
M. Gonzalez, L. Lobos, F. Castillo, L. Galleguillos, N. C. Lopez, and L. Michea
High-Salt Diet Inhibits Expression of Angiotensin Type 2 Receptor in Resistance Arteries
Hypertension, May 1, 2005; 45(5): 853 - 859.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. You, L. Loufrani, C. Baron, B. I. Levy, R. E. Widdop, and D. Henrion
High Blood Pressure Reduction Reverses Angiotensin II Type 2 Receptor-Mediated Vasoconstriction Into Vasodilation in Spontaneously Hypertensive Rats
Circulation, March 1, 2005; 111(8): 1006 - 1011.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. W. Batenburg, I. M. Garrelds, C. C. Bernasconi, L. Juillerat-Jeanneret, J. P. van Kats, P. R. Saxena, and A.H. J. Danser
Angiotensin II Type 2 Receptor-Mediated Vasodilation in Human Coronary Microarteries
Circulation, May 18, 2004; 109(19): 2296 - 2301.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. P. Korovkina, A. M. Brainard, P. Ismail, T. J. Schmidt, and S. K. England
Estradiol Binding to Maxi-K Channels Induces Their Down-regulation via Proteasomal Degradation
J. Biol. Chem., January 9, 2004; 279(2): 1217 - 1223.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Koobi, J. Kalliovalkama, P. Jolma, J. Rysa, H. Ruskoaho, O. Vuolteenaho, M. Kahonen, I. Tikkanen, M. Fan, P. Ylitalo, et al.
AT1 Receptor Blockade Improves Vasorelaxation in Experimental Renal Failure
Hypertension, June 1, 2003; 41(6): 1364 - 1371.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S. P. Bagby, L. S. LeBard, Z. Luo, B. E. Ogden, C. Corless, E. D. McPherson, and R. C. Speth
ANG II AT1 and AT2 receptors in developing kidney of normal microswine
Am J Physiol Renal Physiol, October 1, 2002; 283(4): F755 - F764.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. E. Widdop, K. Matrougui, B. I. Levy, and D. Henrion
AT2 Receptor-Mediated Relaxation Is Preserved After Long-Term AT1 Receptor Blockade
Hypertension, October 1, 2002; 40(4): 516 - 520.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Dimitropoulou, G. Han, A. W. Miller, M. Molero, L. C. Fuchs, R. E. White, and G. O. Carrier
Potassium (BKCa) currents are reduced in microvascular smooth muscle cells from insulin-resistant rats
Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H908 - H917.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimitropoulou, C.
Right arrow Articles by Carrier, G. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimitropoulou, C.
Right arrow Articles by Carrier, G. O.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Ion channels/membrane transport
Right arrow Signal transduction
Right arrow Other Vascular biology